Toxicity of lipopolysaccharide (LPS) (endotoxin) is, to a large extent, mediated by the activation of monocytes/macrophages and subsequent release of monokines, such as interleukin-I (IL-1) and tumor necrosis factor alpha (TNF-a). It is known that LPS binds readily to serum lipoproteins and that LPS-lipoprotein complexes are less toxic than unbound LPS. Here we present data analyzing the impact of the LPS-serum interaction at the cellular level. By measuring IL-1 TNF-a, and IL-6, the interaction of different LPSs or lipid A with human serum could be shown to prevent the activation of human monocytes. The amounts of LPS inactivated by normal human serum did not exceed 10 ng/ml. The LPS-inactivating capacity of serum was shown to be a function of the lipoproteins. Other serum components, such as naturally occurring anti-LPS immunoglobulin G, complement, or nutritive lipids, had no significant influence in our system. Our experiments suggest that serum lipoproteins control endotoxin-induced monocyte activation and monokine release.
Endotoxin (lipopolysaccharide [LPS]
) is the main pathogenic factor of gram-negative bacteria. The most prominent toxic effects of LPS in vivo are fever, diarrhea, and hypotension, which may lead to shock and death. Minimal toxic concentrations of LPS vary widely in mammalian species, with humans being one of the most sensitive. Serum is known to interact with LPS and decrease its toxicity, a fact which has been under investigation since LPS was first isolated more than 30 years ago. In early experiments (31) , inhibition of pyrogenicity was seen after incubation of bacterial polysaccharide with native serum as well as with serum treated at 58°C. One hypothesis was that detoxification of LPS by proteins was due to enzymatic degradation of LPS (34, 45) . This was not, however, supported by other experiments indicating protein-endotoxin complexes, possibly involving immunoglobulins (32) . Later (41) , it was found that LPS detoxification occurred in many different mammalian species, that it was independent of the hemolytic complement system, and that it was optimal at 37°C. Although partial deacylation of LPS may occur inside neutrophils (23) , it seems that LPS molecules, which remain in plasma, do not undergo major cleavage for many hours (20) . It is firmly established that LPS binds to plasma lipoproteins (8, 39) . The evidence for this was first reported by Skarnes in 1968 (33) . LPS binding to lipoproteins, more specifically to the high-density lipoproteins (HDL), has been shown to diminish the LPS toxicity in vivo (20, 24, 38) with respect to pyrogenicity, neutropenia, and anticomplementary activity. Inactivation of LPS by HDL did not, however, proceed to completion, and HDL-complexed LPS retained much of its ability to induce hypotension, disseminated intravascular coagulation, and death.
The actual mechanisms of LPS toxicity are not fully understood. Nevertheless, there is accumulating evidence suggesting that LPS toxicity is mediated by cytokines, namely, tumor necrosis factor alpha-cachectin (TNF-ca), interleukin-1 (IL-1), and IL-6. In vitro, these monokines are * Corresponding author.
concomitantly produced by cells of the monocyte/macrophage lineage, fibroblasts, or endothelial cells upon stimulation by minute amounts of LPS. The central role of monocytes/macrophages in mediating LPS toxicity in vivo has been emphasized by several observations, including adoptive transfer of LPS sensitivity by C3H/HeN macrophages into LPS-nonsensitive C3H/HeJ mice (9) . Further, TNF or IL-1 could mimic the whole spectrum of LPS toxicity in animals (18, 19, 30, 36) , and passive immunization against TNF could prevent some of the LPS toxicity in vivo (4, 21, 37) . IL-6 (previously hepatocyte-stimulating factor) is known to be the principal inducer of the acute-phase response of the liver (12, 13) .
Inhibition of LPS effects by serum components has been demonstrated by several authors (15, 29, 42, 43) , using the Limulus amebocyte lysate assay. Recently, we have shown that under certain conditions, interaction of serum with LPS could prevent LPS-induced mediator release (27, 28) . Pre Preparation of sera. To obtain human serum, blood was drawn from healthy donors (blood group AB or A, checked for absence of irregular antibodies against erythrocytes), collected in bottles, and allowed to clot at 4°C overnight. The serum was withdrawn and frozen at -20°C until tested or immediately used for further preparation. Thawing was performed in a 37°C water bath. Serum fractions separated by ultracentrifugation were tested immediately after preparation. Samples of serum fractions stored at -20°C could also be used and produced equivalent results. Rat serum was obtained from Lewis rats by puncture of the abdominal artery under ether anesthesia and immediately used in experiments. Fetal calf sera (FCS) were purchased from different suppliers and pretested on more than 10 human monocyte preparations for lack of direct IL-1-inducing activity (28) . Only those sera which were negative with all human monocytes were used in our experiments. One of them (lot no. 3R07; Seramed, West Berlin, Federal Republic of Germany) was used throughout the monocyte preparation. All sera were filtered through 0. 45 1640 . In another control, all media and agents (RPMI 1640, serum, LPS, and monocytes) were added at once without any incubation prior to culture. Serum or lipoprotein-free serum was always present at a final concentration of 10%. In reconstitution experiments, the lipoprotein-rich fraction was added to the lipoprotein-free serum to yield concentrations as indicated in the results. The culture supernatants were harvested after 24 h of monocyte culture and stored at -20°C until being tested for monokines.
IL-1 assay. IL-1 was determined in the costimulator assay as described previously (26) . In brief, supernatants were titrated and C3H/HeJ mouse thymocytes were added at 7.5
x 106 cells per ml and incubated for 72 h at 37°C in the presence of suboptimal phytohemagglutinin concentrations (50 pg/ml; no. 27658; Serva, Heidelberg). Cultures were pulsed with [3H]thymidine for the final 24 h. Background levels in the presence of LPS and suboptimal phytohemagglutinin were always less than 800 ± 200 cpm (mean ± standard deviation; done in triplicate). The minimal potentiation accepted as significant was a 2.5-fold increase in incorporated radioactivity over background. International units of IL-1 were calculated by comparison to the international standard for IL-1 (NBSB, Oxford, England) by using a computer-based program (Hochgeladen, Neu-Ulm, Federal Republic of Germany) for logit transformation.
TNF-o assay. TNF-cx was determined by enzyme-linked immunosorbent assay (ELISA) by using a polyclonal rabbit antiserum as described previously (17) .
IL-6 assay. IL-6 was determined by using the IL- (10) . The endotoxins were coupled to microdilution plates (Greiner, Nurtingen, Federal Republic of Germany) at an endotoxin concentration of 70 ,ug/ml (10 ,ug/ml of each LPS) in 100 ,ul per well. The wells were blocked with 10 mg of bovine serum albumin per ml and 1 mg of gelatin per ml in pyrogen-free phosphatebuffered saline. The sera to be tested were diluted 1:100 in phosphate-buffered saline with 20% goat serum. Diluted sera (100 ,u1 per well) were incubated in triplicate at 37°C for 1 h. The bound IgG was detected by peroxidase-labeled goat anti-human IgG (Medac, Hamburg, Federal Republic of Germany) by using o-phenylenediamine (Sigma) as a substrate. Concentrations of anti-LPS antibodies were determined by comparison to a standard of 100 p.g of anti-LPS IgG per ml (a kind gift of S. L. Gaffin). The 10 sera with the largest amounts of anti-LPS IgG showed cross-reactivity to all LPS species used in screening for antibodies, when tested separately.
Complement depletion. Freshly drawn human serum (2-ml aliquots) was either incubated at 56°C for 30 min (to destroy Cl, C2, CS, C8, C9, and factor B), treated with 1 ml of packed baker's yeast at 37°C for 60 min (to deplete native C3), or passed over a controlled pore glass column (Boehringer GmbH, Mannheim, Federal Republic of Germany) coupled with anti-human-C3c antibody (no. A062; Dako, Hamburg, Federal Republic of Germany). The yeast was killed by 56°C for 60 min and washed six times before treatment of the serum. After treatment, the yeast was removed by centrifugation and the serum was incubated for a further 60 min at 37°C. Native control serum was stored on ice until use (approximately 3 h). All samples were passed through 0.22-p.m-pore-size cellulose acetate filters before use in the monocyte assay, and aliquots were tested for total hemolytic complement activity. Complete depletion of complement was achieved by either method. Affinity columntreated serum was also controlled for lack of C3 by rocket immune electrophoresis.
RESULTS
Inactivation of LPS by human serum. Interaction of serum from normal donors with LPS was studied first. Previous experiments (27) 2B ) and IL-6 (Fig. 2C) Activity of IL-1 in these supernatants is depicted on the ordinate. Influence of naturally occurring antibodies against LPS. Almost all human sera contain measurable amounts of anti-LPS antibodies. We investigated whether the naturally occurring antibodies against LPS would interfere with the capacity of LPS to induce IL-1 release. Sera from normal donors with high (>60 ,ug/ml) and low (<5 ,ug/ml) concentrations of anti-LPS IgG determined by ELISA were spiked with the LPS species used to screen for antibodies. The sera were incubated with LPS for 1 h at 4°C to avoid LPS inactivation by lipoproteins and used in monokine production. Comparison of sera with high and low anti-LPS concentrations showed no significant differences in IL-1 induc- vealed that all three sera were equally supportive for monocyte activation by low doses of LPS when LPS was added at the start of the culture (Table 3) . They were also comparable in their capacity to inactivate LPS upon incubation. Heat treatment (56°C, 30 min) of serum showed some influence on the dose of LPS required for IL-1 induction. When 0.1 ng of LPS S. typhi per ml was added at the start of the culture, this dose was no longer sufficient to activate monocytes with this serum. However, heat-treated serum still inactivated LPS upon incubation (Table 3) . Maximum stimulation by a high dose of LPS (-1 V.g/ml; data not shown) was not affected at all, excluding toxicity of heat-treated serum. All sera mentioned in Table 3 were prepared and tested twice. Representative results are shown. Time kinetics experiments were also performed with heat-treated serum. These experiments revealed a slope parallel to that for native serum (data not shown). The results indicate that the complement system, at least starting from C3, is not involved in the LPS inactivation described in this report. This is in agreement with our finding that the capacity to inactivate LPS resides exclusively in the lipoprotein-rich fraction.
DISCUSSION Inflammatory cytokines such as TNF-ot and IL-1 appear to mediate much of the LPS toxicity in vivo, as already pointed out in the introduction. These cytokines are synthesized and (27) . The aim of this study was to give a detailed analysis of the impact of the interaction between LPS and serum on mediator secretion by monocytes in vitro.
Our findings comprise three points. (i) We found that under the conditions used, human serum could prevent the activation of human monocytes by all different species of LPS tested, including a synthetic lipid A, and that all three monokines tested (TNF-ax, IL-1, and IL-6) were affected. We therefore favor the view that inactivation described in this system is not specific for the type of LPS and impairs recognition of LPS by monocytes rather than merely modifying the effect of LPS.
(ii) We found that the complement system and naturally occurring antibodies against LPS are not involved in the inactivation process described in this report. C3-depleted serum and yeast-treated serum both behaved in a way indistinguishable from that of native serum in our assay. This demonstrates that under the conditions used, LPS activation of monocytes, as well as serum inactivation of LPS, were both independent of the complement system, at least starting from C3, although complement may participate in separate pathogenic mechanisms of LPS in vivo. Our results are in agreement with those in a recent publication questioning whether complement could activate monocytes at all (3) . Naturally occurring antibodies which are present in most human sera are also not involved in the inactivation process described, since high-and low-titer antisera, as well as FCS (which contains no antibodies), had LPS-inactivating capacities comparable to that of adult human serum. These results do not exclude the possibility that antibodies may have beneficial effects in vivo by affecting the clearance of LPS or whole microorganisms (22) . Nevertheless, the inability of naturally occurring anti-LPS antibodies to prevent LPS activation of monocytes may contribute to our understanding of why the efficiency of therapy with anti-LPS plasma remains controversial.
Finally, we clearly show that the capacity of normal human serum to inactivate LPS in regard to monokine induction in vitro resides in the lipoproteins. Lipoproteins are the sole fraction in normal human serum to have this capacity, since lipoprotein-free serum did not show any LPS inactivation at all in our system. This does not exclude the possibility that the presence of nonlipoprotein serum components may be necessary or beneficial for the LPS-inactivating function of lipoproteins. Furthermore, components of lipoprotein-free serum have been shown to inactivate LPS in in vitro assays other than monocyte activation and to detoxify LPS in vivo (1, 2, 15, 35 ). The results obtained by different investigators vary considerably, probably depending on the type of LPS, assay system, or in vivo model used (see below). We therefore feel that data from other systems may not be directly transferable to the human model. With the data presented in this paper, we could link LPS-lipoprotein interaction to the inhibition of monocyte activation in a human in vitro model. On the basis of our findings, we speculate that LPS-lipoprotein interaction may well participate in reducing LPS toxicity in humans by suppressing monokine release.
In the present report, we confined ourselves to the investigation of serum from healthy individuals to exclude possible interference from acute-phase proteins, including an LPS-binding protein (35) and a macrophage factor controlling LPS-lipoprotein binding (44) . Such acute-phase proteins, elicited as a response to previous LPS challenge, may interfere with the lipoprotein-dependent LPS inactivation in vitro and may constitute different LPS-inactivating principles in vivo. It is known that the basal level of individual acute-phase proteins present in normal serum varies widely between different species. These differences may well contribute to the massive variation of results in models from different species.
The LPS-inactivating capacity of serum was resistant to 56°C and was optimal at 37°C; this is in agreement with results of in vivo studies (41) . The kinetics of the inactivation were relatively slow. Together with the fact that the presence of serum is often viewed as a prerequisite for optimal culture conditions (6), this may be the reason why LPS inactivation has long gone undetected in systems using monocytes/macrophages. At first glance, the amount of LPS which can be inactivated by normal human serum (about 10 ng/ml) may also not seem very impressive. It may, however, be significant, since monocytes can respond to picogram concentrations of LPS (27) . In relation to the extraordinary sensitivity of monocytes to LPS, the inactivating capacity of serum amounts to between 100-and 1,000-fold.
The amotints of LPS inactivated by serum as described here are in contrast to the vast am,ounts of LPS which can be bound by lipoproteins (39, 40) . The mere binding of LPS to lipoproteins can therefore not be equated with inactivation of LPS. Hence, LPS inactivation as described in this report may represent a distinct biological function of the lipoproteins. Our findings are in agreement with observations from the literature which show that lipoprotein-complexed LPS retained much of its biological activity (21, 25) or its toxicity in animals (24, 38) . The amounts of LPS used in these experiments clearly exceeded the amounts which can be inactivated as judged from our findings.
Using lipoprotein subfractioris, we observed that HDL possess a rather small LPS-inactivating capacity compared with that of the low-density lipoproteins (LDL) (W. A. Flegel, manuscript in preparation). This observation is in contrast to results of binding studies (39) showing that HDL can bind more LPS than LDL can. Extrapolating our observations, we conclude that mere changes in the ratio of lipoprotein classes may considerably alter the LPS-inactivating capacity of total lipoproteins. A relative increase in LDL and decrease in HDL should increase the LPS-inactivating capacity of serum. Changes of composition and levels of serum lipoproteins during the acute-phase response showing the predicted pattern have recently been described (5, 11, 14, 16) .
We believe that lipoproteins are likely to play a role in handling and controlling the everyday influx of LPS from the gut or minor infections. We speculate that lipoproteins constitute a kind of buffer system for LPS, sheltering the organism from being massively activated by minor amounts of LPS, but low enough in their inactivating capacity to allow for sensible activation of the immune system in case of increased influx of LPS. In response to endotoxemia, the inactivation capacity of serum could then be up-regulated by a change of composition or concentration of serum lipoproteins in addition to the generation of other detoxifying principles as mentioned above. Our view of a possible regulation circuit contributing in part to the inactivation of LPS is depicted schematically in Fig. 5 .
In conclusion, we showed that lipoproteins contained in normal human sera can interact with LPS to prevent LPS from activating human monocytes in vitro. Lipoproteins are the sole serum fraction of healthy individuals which has this capacity. The LPS-inactivating capacity of lipoproteins is clearly lower than their capacity to bind LPS. However, in view of the exquisite sensitivity of monocytes to LPS, we favor the concept that lipoproteins constitute a system to control the effects of low doses of LPS on monocyte activation in vivo. A shift of serum lipoprotein levels and composition during the acute phase of an infection might then contribute to an increased detoxification rate of LPS. Republic of Germany, for providing his computer-based program, which proved practical in evaluation of biological assays and determination of IL-1 and IL-6 units.
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